Longaeva Partners’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Longaeva Partners's AVTX Position: Q3 2026 in Review
Longaeva Partners opened a new position in Avalo Therapeutics (AVTX) in Q3 2026: 77,515 shares worth $1.19M. The stake represents 0.02% of the portfolio and ranks #264 among its holdings.
148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Longaeva Partners held 77,515 shares of Avalo Therapeutics worth $1.19M as of Q3 2026.
- Avalo Therapeutics was a new Longaeva Partners position in Q3 2026.
- Avalo Therapeutics made up 0.02% of Longaeva Partners's portfolio in Q3 2026, its #264 holding.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Longaeva Partners's 13F filing for Q3 2026, filed 16 Nov 2026.